Skip to main content
SpringerLink
Log in

Complications of ADT for Prostate Cancer: Hot Flashes

  • Chapter
  • First Online:
Hormone Therapy and Castration Resistance of Prostate Cancer

  • 612 Accesses

Abstract

Hot flashes are often a lasting and distressing side effect of androgen deprivation therapy (ADT) for men with prostate cancer. Hot flashes have been reported in as many as 80% of men with prostate cancer treated with ADT. In men treated with ADT, endorphins may be reduced because of suppression of testosterone levels. This reduction in endorphins may mediate the process of lowering the thermoregulatory set point and ultimately the activation of heat loss mechanisms, resulting in a hot flash. A variety of treatments have been assessed for managing hot flashes, including hormonal therapies, complementary treatments, and nonhormonal drug treatments, such as clonidine, gabapentin, and selective serotonin reuptake inhibitors. However, for hot flashes, there are presently no highly effective mitigating interventions without adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Frisk J. Managing hot flushes in men after prostate cancer. A systematic review. Maturitas. 2010;65:15–22.

    Article  CAS  PubMed  Google Scholar 

  2. Boekhout AH, Beijnen JH, Schellens JH. Symptoms and treatment in cancer therapy-induced early menopause. Oncologist. 2006;11:641–54.

    Article  CAS  PubMed  Google Scholar 

  3. Kadakia KC, Loprinzi CL, Barton DL. Hot flashes: the ongoing search for effective interventions. Menopause. 2012;19:719–21.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Karling P, Hammar M, Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol. 1994;152:1170–3.

    Article  CAS  PubMed  Google Scholar 

  5. Engstrom CA. Hot flashes in prostate cancer: state of the science. Am J Mens Health. 2008;2:122–32.

    Article  PubMed  Google Scholar 

  6. Spetz AC, Zetterlund EL, Varenhorst E, Hammer M. Incidence and management of hot flashes in prostate cancer. J Upport. Oncologia. 2003;1:263–73.

    Google Scholar 

  7. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophisiology and treatment of hot flashes. Mayo Clin Proc. 2002;77:1207–18.

    Article  CAS  PubMed  Google Scholar 

  8. Baum N, Torti D. Management of hot flashes in men with prostate cancer. Geriatri. Aging. 2003;6(2):43–6.

    Google Scholar 

  9. Kagee A, Kruus LK, Malkowicz S, Vaughn DJ, Coyne JC. The experience of hot flashes among prostate cancer patients receiving hormone treatment. Proceedings of the. Proc Am Soc Clin Oncol. 2001;20(2):2999.

    Google Scholar 

  10. Kaplan M, Mahon S, Cope D, Keating E, Hill S, Jacobson M. Putting evidence into practice: evidence-based interventions for hot flashes resulting from cancer therapies. Clin J Oncol Nurs. 2011;15:149–57.

    Article  PubMed  Google Scholar 

  11. Rada G, Capurro D, Pantoja T, Corbalán J, Moreno G, Letelier LM, et al. Non-hormonal interventions for hot f lushes in women with a history of breast cancer. Cochrane Database Syst Rev. 2010;9:CD004923.

    Google Scholar 

  12. Bordeleau L, Pritchard KI, Loprinzi CL, Ennis M, Jugovic O, Warr D, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 2010;28:5147–52.

    Article  CAS  PubMed  Google Scholar 

  13. Moraska AR, Atherton PJ, Szydlo DW, Barton DL, Stella PJ, Rowland KM, et al. Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation study-NCCTG trial N00CB. J Support Oncol. 2010;8:128–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-Töns JH, Adriaansz S, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebocontrolled trial. J Clin Oncol. 2011;29:3862–8.

    Article  CAS  PubMed  Google Scholar 

  15. Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 2010;11:147–54.

    Article  CAS  PubMed  Google Scholar 

  16. Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O'Boyle PJ. A prospective, randomized study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol. 1996;29:47–54.

    Article  CAS  PubMed  Google Scholar 

  17. Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994;331:347–52.

    Article  CAS  PubMed  Google Scholar 

  18. Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, et al. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer. Urology. 2009;73:635–40.

    Article  PubMed  Google Scholar 

  19. Lee MS, Kim KH, Shin BC, Choi SM, Ernst E. Acupuncture for treating hot flushes in men with prostate cancer: a systematic review. Support Care Cancer. 2009;17:763–70.

    Article  PubMed  Google Scholar 

  20. Harding C, Harris A, Chadwick D. Auricular acupuncture: a novel treatment for vasomotor symptoms associated with luteinizing hormone releasing hormone agonist treatment for prostate cancer. BJU Int. 2009;103:186–90.

    Article  PubMed  Google Scholar 

  21. Ashamalla H, Jiang ML, Guirguis A, Peluso F, Ashamalla M. Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy. Int J Radiat Oncol Biol Phys. 2011;79:1358–63.

    Article  PubMed  Google Scholar 

  22. Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause. 2012;19(7):749–59.

    Article  PubMed  Google Scholar 

  23. Mann E, Smith MJ, Hellier J, Balabanovic JA, Hamed H, Grunfeld EA, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13(3):309–18.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Duijts SF, van Beurden M, Oldenburg HS, Hunter MS, Kieffer JM, Stuiver MM, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatmentinduced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol. 2012;30(33):4124–33.

    Article  PubMed  Google Scholar 

  25. Stefanopoulou E, Yousaf O, Grunfeld EA, Hunter MSA. Randomised controlled trial of a brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN). Psycho-Oncology. 2015;24:1159–66.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Sharma P, Wisniewski A, Braga-Basaria M, Xu X, Yep M, Denmeade S, et al. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol. 2009;182:2265–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Vitolins MZ, Griffin L, Tomlinson WV, Vuky J, Adams PT, Moose D, et al. Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer. J Clin Oncol. 2013;31:4092–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Hideki Sakai & Tomoaki Hakariya

Authors
  1. Hideki Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomoaki Hakariya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideki Sakai .

Editor information

Editors and Affiliations

  1. Department of Urology, Tohoku University School of Medicine, Sendai, Japan

    Yoichi Arai

  2. Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Osamu Ogawa

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sakai, H., Hakariya, T. (2018). Complications of ADT for Prostate Cancer: Hot Flashes. In: Arai, Y., Ogawa, O. (eds) Hormone Therapy and Castration Resistance of Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-7013-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7013-6_15

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7012-9

  • Online ISBN: 978-981-10-7013-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation